Hsu Po-Ke, Wu Chia-Lin, Yang Yu-Hsuan, Wei James Cheng-Chung
Institute of Medicine, Chung Shan Medical University, Taichung 40201, Taiwan.
Department of Weight Control Center, Sun Saint Clinic, Zhubei City 302052, Taiwan.
J Clin Med. 2022 Jun 10;11(12):3325. doi: 10.3390/jcm11123325.
(1) Background/aims: Intragastric botulinum toxin A injection (IGBI) combined with diet control is a new and effective weight loss method for grade 2 obese patients. However, the application of IGIB on overweight or obese adults still needs further research to confirm its efficacy. (2) Methods: We retrospectively collected medical data from 1 July 2021 to 1 January 2022 from a total of 71 patients without diabetes who participated in the bariatric clinic with a body mass index (BMI) > 25 kg/m2. Forty-nine participants opted for intragastric botulinum injection (IGBI) using 300 units of botulinum injected into the antrum, body, and fundus, followed with a low-calorie high-protein diet course. Another 22 people participated only in the low-calorie high-protein diet course as a placebo group. This study analyzes the weight loss percentage of the two groups. Adverse events after IGBI are also reported in a safety assessment. (3) Results: In terms of the characteristics of the two groups, the mean BMI was 29.3 kg/m2 in the IGBI group and 28.0 kg/m in the placebo group (p = 0.63 without significant difference). Comparing the percent weight loss from baseline in the two groups after 12 weeks, the IGBI group lost 11.5% of their body weight and the placebo group lost 1.8%. In terms of group analysis, the percentages of participants with a weight reduction of at least 5% for the IGBI and placebo groups were 95% and 4%, respectively. For weight reduction of at least 10%, these values for the IGBI and placebo groups were 63% and 4%, respectively. In terms of adverse events after IGBI for 12 weeks, 12 participants (24.4%) had constipation, which was the main side effect. No serious adverse events were observed during the study period. (4) Conclusion: The combination of a low-calorie high-protein diet and IGBI is an effective and safe procedure in overweight or obese adults for weight reduction, but further larger studies are needed.
（1）背景/目的：胃内注射肉毒杆菌毒素A（IGBI）联合饮食控制是一种针对2级肥胖患者的新型有效减肥方法。然而，IGBI在超重或肥胖成年人中的应用仍需进一步研究以证实其疗效。（2）方法：我们回顾性收集了2021年7月1日至2022年1月1日期间，共71名无糖尿病且体重指数（BMI）>25 kg/m²的参加减肥门诊患者的医疗数据。49名参与者选择胃内注射肉毒杆菌毒素（IGBI），将300单位肉毒杆菌毒素注入胃窦、胃体和胃底，随后进行低热量高蛋白饮食疗程。另外22人仅参加低热量高蛋白饮食疗程作为安慰剂组。本研究分析了两组的体重减轻百分比。在安全性评估中还报告了IGBI后的不良事件。（3）结果：就两组的特征而言，IGBI组的平均BMI为29.3 kg/m²，安慰剂组为28.0 kg/m²（p = 0.63，无显著差异）。比较两组在12周后相对于基线的体重减轻百分比，IGBI组体重减轻了11.5%，安慰剂组体重减轻了1.8%。在分组分析方面，IGBI组和安慰剂组体重减轻至少5%的参与者百分比分别为95%和4%。对于体重减轻至少10%的情况，IGBI组和安慰剂组的这些值分别为63%和4%。就IGBI 12周后的不良事件而言，12名参与者（24.4%）出现便秘，这是主要副作用。在研究期间未观察到严重不良事件。（4）结论：低热量高蛋白饮食与IGBI相结合在超重或肥胖成年人中是一种有效且安全的减肥方法，但需要进一步开展更大规模的研究。
